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Background: Mesothelioma is an incurable cancer originating from the mesothelial cells that line the pleural, peritoneal and
pericardial cavities. These cells synthesise large quantities of surface glycoproteins, rendering them dependent upon efficient
endoplasmic reticulum (ER) function. When faced with elevated levels of secretory protein load, cells are said to experience ER
stress, which has been implicated in the pathogenesis of many human diseases including cancer.
Method: We set out to measure markers of ER stress in malignant mesothelioma and to determine whether ER stress signalling
correlates with clinical parameters.
Results: We observed that expression of the ER stress-responsive transcription factor C/EBP homologous protein (CHOP)
correlated with patient survival and remained an independent prognostic variable in pairwise comparisons with all clinical
variables tested. The most parsimonious multivariate model in our study comprised only performance status and CHOP staining.
In contrast, expression of the ER stress-responsive phosphatase growth arrest and DNA damage 34 (GADD34) correlated with the
degree of mesothelial differentiation, being lost progressively in biphasic and sarcomatoid mesotheliomas.
Conclusion: Our findings suggest that staining for CHOP provides prognostic information that may be useful in the stratification
of patients with mesothelioma. Staining for GADD34 may prove useful in classification of mesothelioma histopathology.
The worldwide incidence of malignant mesothelioma is increasing
and in the UK is expected to peak at over 3000 cases per annum
within 5 years (Hodgson et al, 2005). However, it will continue to
pose a global public health threat for decades thereafter, owing to
the continued use of asbestos in developing economies. Much work
has focused on developing new therapies, both pharmacological
and surgical, yet clinical outcomes remain dire. Without a better
understanding of the fundamental biology of this cancer, it is
unlikely that significant breakthroughs will occur.
In vitro studies have shown that selective inhibition of the
proteasome with the drug bortezomib will induce cell-cycle arrest
in cultured malignant mesothelioma cell lines (Gordon et al, 2008).
Although the mechanism remains unclear, when used to treat
drug-resistant cases of malignant myeloma, bortezomib has been
shown to induce endoplasmic reticulum (ER) stress, which can
trigger both cell-cycle arrest and cell death (Obeng et al, 2006).
Endoplasmic reticulum stress is now recognised to have a role in
the pathophysiology of many human diseases including cancer
(Marciniak and Ron, 2006). This reflects both increased protein
misfolding within hypoxic solid tumours and dysregulation of the
secretory pathway in malignant cells (Bi et al, 2005; Obeng et al,
2006). Moreover, an intact ER stress-signalling pathway is
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necessary for the growth of some tumours (Bi et al, 2005). The
adaptive response to ER stress, or ‘unfolded protein response’,
comprises mechanisms to regulate new protein translation and to
induce genes that enable adaptation to stress (Marciniak and Ron,
2006; Marcinak and Ron, 2010). Mesothelial cells generate large
quantities of surface glycoproteins to help lubricate the pleural
space, and so dysregulation of their synthesis is likely to be
associated with ER stress.
Endoplasmic reticulum stress activates multiple transmembrane
sensors including protein kinase R-like kinase (PERK) (Marciniak
and Ron, 2006). PERK mediates inhibition of global protein
translation through phosphorylation of eukaryotic translation
initiation factor 2a (eIF2a), which reduces the load of newly
synthesised proteins entering the ER lumen (Shi et al, 1998;
Harding et al, 1999). Once phosphorylated, eIF2a is unable to
support new protein synthesis (Hinnebusch, 2000); although a
subset of ER stress-responsive proteins including transcription
factor C/EBP homologous protein (CHOP) is induced under these
conditions (Wang et al, 1996). Target genes of CHOP, which
include growth arrest of DNA damage 34 (GADD34), appear to
have a role in the toxicity seen during chronic ER stress, because
cells lacking CHOP are protected from ER-stress-induced death
(Zinszner et al, 1998; Marciniak et al, 2004).
We hypothesised that markers of ER stress in biopsy specimens
from cases of malignant mesothelioma would reflect the
endogenous level of ER stress signalling within the tumour and
provide prognostic information. We chose to measure protein
expression of CHOP, GADD34 and BiP in formalin-fixed paraffin-
embedded (FFPE) samples, because CHOP and GADD34 have
both been linked with the toxic consequences of ER stress, whereas
BiP levels are known to correlate with cytoprotection. Herein, we
report that GADD34 expression is correlated with the degree of
mesothelial cell differentiation, whereas CHOP expression is an
independent predictor of prognosis in malignant mesothelioma.
MATERIALS AND METHODS
Ethics and consent. Ethical approval for the use of samples and
data collection was granted by the Research Ethics Committee
(REC reference 09/H0311/21). All cases of malignant mesothe-
lioma diagnosed at Papworth Hospital (Cambridge, UK) between
2005 and 2010 were identified from hospital records, and the FFPE
biopsy tissue blocks were retrieved from the pathology department
store along with their associated histology slides. Clinical data
relating to the cases were extracted from hospital records.
Antibodies. The antibodies used in this study were: rabbit
polyclonal anti-GADD34 1 : 100 (10449-1-AP; Proteintech, Chi-
cago, IL, USA); rabbit monoclonal anti-BiP 1 : 200 (C50B12; Cell
Signaling Technology, Boston, MA, USA); and rabbit polyclonal
Tg
BiP
CHOP
50 m
GADD34
– +
Figure 1. Endoplasmic reticulum stress and its detection in FFPE
samples. Human HCT116 cell clots were generated using human
plasma and thrombin from unstressed cells and cells treated
with 400nM thapsigargin (Tg) to induce ER stress. Clots were
fixed in formalin and embedded in paraffin to mimic the preparation
of biopsy material. These were used to identify antibodies
capable of distinguishing unstressed from ER-stressed cells
by immunohistochemistry for BiP, CHOP and GADD34. Scale bar
indicates 50mm.
Table 1. Patient characteristics
Number
of patients
Number of
patients
available (%)
Gender 135
Male 109 80.7
Female 26 19.3
Histogy 135
Epithelioid 100 74.1
Biphasic 22 16.3
Sarcomatoid 13 9.6
Smoking status 127
Ex-smoker 79 62.2
Current 11 8.7
Never 37 29.1
Asbestos exposure 135
Yes 94 69.6
ECOG performance status 100
0 34 34.0
1 43 43.0
2 16 16.0
3 7 7.0
CT stage 84
I 17 20.2
II 15 17.9
III 29 34.5
IV 23 27.4
Chemotherapy 103
Yes 39 37.9
No 64 62.1
Alive 135
Yes 12 8.9
WCC 128
48.3 84 65.6
Abbreviations: CT¼ computed tomography; EORTC¼European Organisation for Research
and Treatment of Cancer; WCC¼white cell count.
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anti-GADD153/CHOP 1 : 300 (ab59396; Abcam, Cambridge, UK).
The following antibodies were tested using various conditions but
were ineffective in detecting differences in antigen expression in
response to ER stress: rabbit polyclonal anti-PPP1R15A/GADD34
(HPA202240, Prestige antibodies; Sigma, Dorset, UK); rabbit
polyclonal anti-GADD34 (SC-824; Santa Cruz Technologies, Inc.,
Santa Cruz, CA, USA); and mouse monoclonal anti-GADD153/
CHOP (ab11419; Abcam).
Cell clots. Cultured cells were collected by trypsinisation and
pelleted by centrifugation, washed with PBS and resuspended in
Cytofix reagent (Surgipath, Milton Keynes, UK) for at least 2 h at
room temperature. Cell clots were generated from these fixed cells
by the addition of human plasma and bovine thrombin (Diagen
Diagnostic Reagents Ltd, Oxfordshire, UK) with incubation at
37 1C until clot formation. The clot was fixed in 10% v/v formalin,
dehydrated through serial ethanol washes and embedded in
paraffin wax.
Tissue microarray. One-hundred and thirty-five cases of malig-
nant mesothelioma were included in the study. For each tissue
block, a haematoxylin and eosin-stained section was re-examined
by an experienced histopathologist, and at least three representa-
tive regions of tumour were identified. Cores of tissue measuring
0.6mm in diameter were taken from each region of each block and
were used to generate a tissue microarray (TMA) comprising three
blocks. Normal pleura, liver and kidney controls were distributed
at random intervals throughout the TMA. Sections of 3mm were
prepared and stained as detailed below. Every 50th section was
stained with haematoxylin and eosin for monitoring of morphol-
ogy and quality of cores.
Immunohistochemistry. Sections were baked in an oven at 65 1C
for 1 h. PT link tanks (Dako, Glostrup, Denmark) were used to
perform deparaffinisation and heat-induced epitope retrieval
(EnVision FLEX Target Retrieval Solution High pH; Dako). All
slides were incubated for 20min at 97 1C and left in buffer
(EnVision FLEX wash buffer; Dako) at room temperature for a
minimum of 5min to cool down. Staining was performed using an
automated immunostainer (AutostainerLink48; Dako). The proto-
col was as follows: slides were incubated for 5min in an
endogenous block (EnVision FLEX peroxidase-blocking reagent;
Dako) and then incubated with antibody for 30min. MNF116,
mesothelin, vimentin and calretinin had an additional step of
incubating sections with mouse linker (EnVision FLEX/mouse
(linker); Dako) for 15min. Then all sections were incubated for
30min in labelled polymer (EnVision FLEX/HRP; Dako). Each
individual stage was followed by buffer rinses (EnVision FLEX
wash buffer; Dako). Staining was visualised using the chromogen
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Figure 2. Mesothelioma patient characteristics and prognosis. Kaplan–Meier curves corresponding to demographic data. (A) ECOG performance
status (0, blue; 1, green; 2, purple; and 3, orange). (B) EORTC prognostic score¼ 0.55 (if white cell count 48.3109 cells per l)þ0.6 (ECOG
performance status is 1 or 2)þ0.52 (if histology probable)þ 0.60 (if histology is sarcomatoid)þ 0.60 (if gender is male); low o1.27, high Z1.27
(Fennell et al, 2005). (C) Histological sub-type. (D) Histological sub-type with sarcomatoid and biphasic combined as ‘not epithelioid’. Statistical
significance is indicated in figures A–D, top right. Univariate survival analysis used the log-rank test. Points censored from the statistics because the
patient remained alive at the time of analysis are indicated as crosses.
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Figure 3. Tissue microarray stained for markers of ER stress. (A) Tissue microarray of 0.6mm cores of representative epithelioid, sarcomatoid and
biphasic malignant mesothelioma stained with H&E 40 (insert box  100). (B) Representative images of tissue microarray cores stained for BiP,
CHOP and GADD34, indicating intensities scored from 0 to 3 after the method by Allred et al (1998): 0, negative; 1, detectable but weak; 2,
moderate but submaximal; or 3,maximal;  40 (insert 100).
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3,30-diaminobenzidine for 10min, counterstained with haematox-
ylin (EnVision FLEX; Dako) for 5min and manually cover-slipped
(Surgipath) with DePeX mounting medium (VWR International,
Poole, UK).
To quantify ER stress signalling in FFPE tissue samples, we
tested the specificity of commercially available antibodies against
the antigens BiP, CHOP and GADD34. To this end, human
HCT116 cells and mouse embryonic fibroblasts were cultured
under basal conditions or conditions known to induce ER stress.
Thapsigargin inhibits the sarco/endoplasmic reticulum calcium
ATPase that maintains ER luminal calcium levels, and so induces
ER stress by causing depletion of ER calcium. Based on previous
studies, under basal conditions, HCT116 cells were expected to
show no or very low expression of CHOP and GADD34 with
modest expression of BiP (Novoa et al, 2001, 2003; Harding et al,
2002; Marciniak et al, 2004). Antibodies for BiP, CHOP and
GADD34 were examined for their ability to distinguish between
unstressed cells and ER stressed cells (Figure 1). To mimic FFPE
biopsy material, cell clots were fixed in formalin and embedded in
paraffin. An antibody was assessed as detecting its antigen only if
staining were higher in ER-stressed cells compared with controls.
Antibodies tested that failed to pass these criteria are listed in
Materials and Methods. For each antigen, the antibodies capable of
reliably identifying ER-stressed FFPE samples were: rabbit
polyclonal anti-GADD34 (10449-1-AP; Proteintech); rabbit mono-
clonal anti-BiP (C50B12; Cell Signaling Technology); and rabbit
polyclonal anti-GADD153/CHOP (ab59396; Abcam).
Scoring and statistical analysis. Survival was assessed from the
date of histological diagnosis. Data analysis was performed with
SPSS v17.0 (SPSS Inc., Woking, UK) and the R software
environment. Univariate survival analysis used the log-rank test
(LR), and multivariable analysis was performed by Cox regression
using a forward stepwise model based on likelihood ratios. Results
were displayed graphically as Kaplan–Meier curves or box-and-
whisker plots. To assess the utility of CHOP score as a prognostic
marker, C-statistics (area under the ROC curve) were estimated
from logistic regression models fitted to 1-year survival outcomes.
A C-statistic value of 0.5 represents chance, whereas 40.65 is
considered clinical relevant (Nowak et al, 2010). Estimated
C-statistics, 95% CIs and P-values for testing whether addition of
CHOP significantly increased the C-statistic were calculated using
the pROC package in R (Robin et al, 2011). The predictive value of
models was assessed using C-statistic calculated from receiver
operator curve analysis, with median survival as the bivariate state
variable. Differences in staining scores between histological groups
were assessed by ANOVA with Bonferroni post-hoc test.
Correlations between staining scores and histological subtypes
were assessed by Spearman’s correlation coefficient. P-valueso0.05
were considered statistically significant.
RESULTS
Patients represented in the mesothelioma tissue microarray.
Tissue blocks were identified for 135 cases of malignant
mesothelioma biopsied at Papworth Hospital between 2005 and
2010. Of these, 84 had tumour tissue on at least one level of the
TMA. In all cases where cores lacked tumour cells, the original
material had been from CT-guided needle biopsies. Clinical data
were complete to August 2012. The demographics of this group are
presented in Table 1 and Figure 2. Consistent with the known
epidemiology of malignant mesothelioma, most patients were male
(80.7%), had a positive history of exposure to asbestos (69.6%) and
had a median age of 70 years at the time of diagnosis (Table 1). The
majority of cases had a positive smoking history (70.1%), but only
a minority were current smokers at the time of biopsy (8.7%). Most
cases had a good performance status of 0 or 1 at the time of
diagnosis (77%). Tumour International Mesothelioma Interest
Group stage determined by CT scan at presentation was advanced
(stages II–IV) in the majority of patients (79.8%). Twelve patients
(8.9%) were alive at the time of data analysis.
Detection of ER stress markers in malignant mesothelioma.
Scoring of the TMA for markers of ER stress was performed in
parallel by two observers (LED and DMR) blinded to the clinical
data. For each core and each antigen, intensity of tumour staining
was evaluated on a scale from 0 to 3 after the method by Allred
et al (1998): 0, negative; 1, detectable but weak; 2, moderate but
submaximal; or 3, maximal (Figure 3). In addition, the extent of
staining was recorded as the proportion of malignant cells staining.
Staining scores for each antigen were calculated as the sum of each
intensity multiplied by the percentage of positive cells of that
intensity, giving a range from 0 (0 100%) to 300 (3 100%). The
score used in all subsequent analysis was the average across the
available cores. When TMA slides were probed for expression of
BiP, CHOP and GADD34, each showed a significant relationship
with histological subtype (Figure 4). There was a positive
correlation between GADD34 immunoreactivity and mesothelial
differentiation status (Spearman’s correlation coefficient 0.513;
P¼ 0.000). GADD34 staining was significantly stronger in
epithelial mesothelioma compared either with biphasic tumours
(Po0.001) or with sarcomatoid tumours (Po0.005). BiP also
showed correlation with mesothelial differentiation, but this
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Figure 4. Correlation of ER stress markers with histological subtype. Box-and-whiskers plot of staining scores for BiP, GADD34 and CHOP in
epithelioid, bisphasic and sarcomatoid mesothelioma. Statistical differences were calculated by ANOVA with Bonferroni post-hoc test.
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was less pronounced (Spearman’s correlation coefficient
0.425; P¼ 0.000). In contrast, staining for CHOP displayed a
weak inverse correlation with mesothelial differentiation (Spear-
man’s correlation coefficient  0.333; Po0.006).
Univariate analysis. Baseline demographic characteristics with
prognostic significance on univariate analysis were histological
subtype (Po0.001), current smoking (P¼ 0.01), Eastern Coopera-
tive Oncology Group (ECOG) performance status (Po0.001),
radiographic stage (CT stage) (P¼ 0.008 for stages individually;
P¼ 0.004 for stage IV vs I–III) and referral for chemotherapy
(Po0.001) (Table 2). In isolation, age and gender did not have an
impact on survival (Supplementary Figure S1); however, as noted
previously (Fennell et al, 2005), the composite European
Organisation for Research and Treatment of Cancer (EORTC)
prognostic score, which combines age, gender, histology, prob-
ability of diagnosis and leucocyte count, correlated significantly
with prognoses (P¼ 0.002 as a continuous variable and Po0.001
using the validated threshold of 1.27) (Fennell et al, 2005) (Table 2,
Figure 2B).
For the purposes of univariate analysis, histological scores were
grouped into quintiles. Only CHOP score quintiles were associated
with prognosis (P¼ 0.005). Those cases staining in the top quartile
of intensities had a median survival significantly shorter than that
of the rest of the cohort (145±17 vs 486±55 days, P¼ 0.002;
Figure 5A–D). When cases were stratified by stage, a statistically
significant difference persisted for early stage (stage I and II)
(Figure 5E–H).
Multivariate analysis. In multivariate analysis by Cox regression,
CHOP score was a significant predictor of survival independent
of histology, smoking, ECOG performance status, chemotherapy
and EORTC prognostic score (Table 3). CT stage and chemother-
apy were redundant when models included CHOP score. When
CHOP score, performance status, histology, smoking and EORTC
prognostic score were considered simultaneously using a forward
stepwise model, the most parsimonious model retained only
CHOP score and performance status (HRCHOP score 0.332,
P¼ 0.014; HRperformance status 2.501, P¼ 0.000; n¼ 46). However,
the addition of CHOP score to logistic regression models of other
prognostic factors improved the C-statistic significantly only in the
case of radiological staging (Table 4).
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Figure 5. CHOP score predicts prognosis. Kaplan–Meier curves and
box-and-whiskers plots of mesothelioma patient groups defined by
CHOP score. (A, B) Upper (green) and lower (blue) quintiles of CHOP
score. Median survivals±s.e.: CHOP high 145±0.17 days; CHOP low
486±48 days. (C, D) Upper quintile (green) and remaining cases (blue).
Median survival±s.e.: CHOP high 145±0.17 days; CHOP low 486±
55 days. Censored cases are represented by crosses. (E–H) Survival of
CHOP-defined groups stratified by stage. (E, F) Stages I and II
combined: CHOP high 145±45 days; CHOP low 568±145 days.
(G, H) Stages III and IV combined: CHOP low 284±100 days;
CHOP low 536±127 days.
Table 2. Parameters influencing survival in univariate analysis
Parameter Cut-off P-value
Histology All subtypes 0.000
Non-epithelioid 0.000
Smoking All groups 0.031
Current smoker 0.010
ECOG PS All groups 0.000
0–1 vs 2–3 0.000
CT stage All groups 0.008
I–III vs IV 0.004
Chemotherapy Given 0.001
EORTC prognostic score All groups 0.002
o1.27 0.000
CHOP score All quintiles 0.005
Top vs bottom quintiles 0.006
Top quintile vs remainder 0.002
Abbreviations: CHOP¼C/EBP homologous protein; CT¼ computed tomography;
EORTC¼European Organisation for Research and Treatment of Cancer; PS¼performance
status.
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DISCUSSION
In this study, we have examined the expression levels of markers of
ER stress in malignant mesothelioma, and correlated this with
survival times. Levels of GADD34 correlated with mesothelial
differentiation, whereas levels of CHOP staining predicted
prognosis-independent histological subtype. Previous work has
suggested that GADD34 may function as a tumour suppressor
through its growth arrest and pro-apoptotic properties (Fornace
et al, 1989; Zhan et al, 1994; Hollander et al, 1997; Su et al, 1997),
although in our study it was not an independent predictor of
survival. This may reflect a lack of statistical power, because
selection of cases with the least GADD34 staining using an
empirical cutoff of 175 appeared to identify a group with poor
prognosis (not shown). Unfortunately, because of the rarity of
mesothelioma, our cohort could not be efficiently divided into
discovery and validation sets, and therefore this finding remains
speculative and requires future validation. The close correlation
between GADD34 staining and histological subtype suggests that
GADD34 is unlikely to be an independent variable. Nevertheless,
this correlation may indicate an important mechanistic link
between loss of mesothelial differentiation and tumour aggressive-
ness. It is tempting to speculate that correction of the deficit of
GADD34 might have therapeutic benefit. Indeed, treatment with
chemotherapy and radiotherapy has previously been shown to
upregulate GADD34 expression in cancer cells and to promote
increased oncolytic viral replication, presumably through antag-
onising the antiviral effects of PKR (Adusumilli et al, 2006, 2007).
It is noteworthy that during an effort to identify genes involved in
tumour progression, an N-terminal truncated sequence of
GADD34 was identified by subtractive hybridisation from a rat
embryonic cell line (Su et al, 1997). This transcript, which was
named progression elevated gene-3, was found to enhance tumour
aggressiveness and promote angiogenesis in vivo (Su et al, 1999).
Similar truncating mutations of GADD34 are frequent occurrences
during transformation of rat cell lines (Su et al, 2005). The
mechanism for the tumour-promoting activity is unclear but might
plausibly involve a dominant-negative interaction with endogenous
GADD34. We did not specifically attempt to detect this product of
the GADD34 gene, and the antibody we used to detect GADD34 in
histological specimens had been raised against a fusion protein,
containing residues 304–569 of the 654 amino-acid human
GADD34, and so would not have recognised most of the
N-terminal portion of the protein.
Although GADD34 is a transcriptional target of CHOP in
the context of cellular stress (Marciniak et al, 2004), the two
proteins demonstrated a weak reciprocal relationship in relation
to mesothelial differentiation. It is possible that expression of
GADD34 in benign mesothelium in vivo and in epithelioid
malignant mesothelioma might occur through the alternate
signalling pathways. Alternatively, the failure to express GADD34
through as-yet unidentified malignant processes might exaggerate
the CHOP signal caused by ER stress. Since the transcriptional
programme of CHOP includes at least 200 additional targets
(Marciniak et al, 2004), it is possible that their overexpression in
such circumstances might contribute to adaptation of the tumour
to ER stress and thus promote tumour growth.
In summary, we have constructed a TMA of a series of cases of
malignant mesothelioma, and used this to examine the expression
levels of markers of ER stress in this cancer. Our results suggest
that CHOP may represent a useful biomarker of tumour
aggression. This may prove useful in patient stratification and
the development of anticancer strategies aimed at modulating ER
stress, for example, the use of proteasome inhibitors and newer
agents such as inhibitors of HSP90. The correlation of GADD34
with mesothelial differentiation may prove useful in the sub-
classification of borderline histological cases.
Table 4. C-statistic value for the prediction of reaching median survival
Model C-statistic DC (P-value) CI 95% low CI 95% high
CHOP top quintile 0.649 0.555 0.743
Histology (all types) 0.706 0.606 0.801
Histology (all types)þCHOP top quintile 0.750 0.050 (ns) 0.653 0.859
ECOG PS 0.826 0.712 0.941
ECOGþCHOP top quintile 0.895 0.069 (ns) 0.805 0.985
EORTC score o1.27 0.667 0.567 0.767
EORTC score o1.27þCHOP top quintile 0.718 0.052 (ns) 0.613 0.825
CT stage (all) 0.748 0.581 0.915
CT stage (all)þCHOP 0.855 0.107 (ns) 0.725 0.985
CT stage (I–III vs IV) 0.608 0.483 0.797
CT stage (I–III vs IV)þCHOP 0.797 0.188 (0.011) 0.657 0.936
Abbreviations: CHOP¼C/EBP homologous protein; CI¼ confidence interval; CT¼ computed tomography; EORTC, European Organisation for Research and Treatment of Cancer; ns¼not
statistically significant. DC indicates difference in C-statistic from reference value due to addition of CHOP score to the model.
Table 3. Prognostic models involving pairwise combinations including
CHOP score
Paired comparison
HR
(Exp(B))
95%
CI low
95%
CI high P-value n
CHOP score 0.469 0.243 0.902 0.023 67
Histology 1.939 1.243 3.023 0.003
CHOP score 0.457 0.240 0.870 0.017 65
Smoking 1.647 1.021 2.657 0.041
CHOP score 0.383 0.162 0.908 0.000 48
ECOG performance
status
2.646 1.725 4.061 0.000
CHOP score 0.430 0.228 0.812 0.009 67
EORTC prognostic
score
3.477 1.845 6.550 0.000
CHOP score 0.424 0.225 0.799 0.008 67
EORTC prognostic
score o1.27
2.289 1.239 4.229 0.008
Abbreviations: CI¼ confidence interval; EORTC¼European Organisation for Research and
Treatment of Cancer; Exp(B)¼ exponentiation of the B coefficient; HR¼ hazard ratio.
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